Impact of the Council of Europe Resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients

Abstract

Introduction and objectiveThe regulation of pharmacy preparations, especially for standards for quality assurance and safety, is not harmonised across Europe and falls under the national competencies of individual states. There are concerns about quality control and safety for the medicinal products made in pharmacies, which is widespread in European countries. There are, however, good reasons to continue this practice, which is able to tailor preparations to the specific needs of a particular patient or patient group and to provide a supplementary source of supply when an industrially manufactured product, which is authorised for marketing is not available or when there are temporary shortages of licensed medicines. In seeking to provide guidelines for legislation and acting on the advice of an expert group dealing in pharmaceutical practices, the Committee of Ministers of the Council of Europe passed a resolution in 2011. The Council of Europe Resolution provides authorities and pharmacists with the means to reinforce safety measures for medicinal products prepared in pharmacies and to harmonise quality assurance and safety standards. It dealt with aspects of pharmacy preparation such as quality standards for preparation and distribution, marketing authorisation, product dossiers, labelling, reporting, and safety. In 2013 and 2014 the Committee of Experts carried out a survey to evaluate the impact of the resolution within a cross section of member states. The objectives of this study were both to monitor the extent to which the recommendations had been enshrined in national legislation and also to understand current differences in legislation and practice between the member states.MethodsIn the resolution of 2011 the member states were recommended to adapt their legislation in line with its provisions. The survey that was carried out in 2013 and 2014 followed the recommendations in the resolution. A questionnaire was made and sent to a cross section of member states.ResultsAmong the member states involved, the results of this survey show a clear commitment to implement the recommendations of the resolution.ConclusionsThis report presents the results of the survey with a discussion of outstanding issues.

A systematic review and meta-analysis of microbial contamination of parenteral medication prepared in a clinical versus pharmacy environment

“…As already mentioned, different guidelines exists for preparation of parenteral products in clinical environment across Europe. But also to pharmacy preparations differences exists in practice and legislation across Europe [51].…”

Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution

“…However, it is common practice throughout member states to allow pharmacy preparations for the treatment of patients for which no licensed medicinal product is available on the market 4. Further evaluation is required to see whether the pharmacy preparations and the related national policies are in line with current EU legislation and the Resolution, and the consequences thereof.…”

Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics

“…Therefore, high‐quality magistral preparations for hospital and community pharmacies (where it is still feasible) will be required today and in the future. The Council of Europe, in which there are many more member states than in the European Union, has filed a resolution for the preparation of medicinal products in pharmacies in order to standardize and to improve quality and to ensure the safety of extemporaneous preparations . At the European Directorate for the Quality of Medicines, a working group has been established to generate a pediatric formulary based on predefined specifications with recipes of high‐standard and well‐established preparations.…”